About Smilax Laboratories
Smilax Laboratories is a company based in Hyderabad (India) founded in 2005 by Suryadevara Krishna. Smilax Laboratories has raised $14.04 million across 3 funding rounds from investors including Mumbai Waste Management, TNWML and Ramky Finance And Investment. The company has 521 employees as of April 10, 2024. Smilax Laboratories offers products and services including APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services. Smilax Laboratories operates in a competitive market with competitors including Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
- Headquarter Hyderabad, India
- Employees 521 as on 10 Apr, 2024
- Founders Suryadevara Krishna
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Smilax Laboratories Limited
- Date of Incorporation 20 Oct, 2004
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$32.15 M (USD)33.66as on Mar 31, 2023
-
Net Profit
$452.84 K (USD)129.33as on Mar 31, 2023
-
EBITDA
$1.31 M (USD)216.49as on Mar 31, 2023
-
Total Equity Funding
$14.04 M (USD)
in 3 rounds
-
Latest Funding Round
$7.61 M (USD), Series A
Nov 10, 2017
-
Investors
Mumbai Waste Management
& 10 more
-
Employee Count
521
as on Apr 10, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Smilax Laboratories
Smilax Laboratories offers a comprehensive portfolio of products and services, including APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services.
Manufactures active ingredients for global generic drugs market
Provides intermediates for pharmaceutical API production worldwide
Offers pellets and granules for drug delivery in generics
Delivers custom manufacturing for pharmaceutical companies globally
Funding Insights of Smilax Laboratories
Smilax Laboratories has successfully raised a total of $14.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $7.61 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Smilax Laboratories
Smilax Laboratories has secured backing from 11 investors, including institutional and angel investors. Prominent investors backing the company include Mumbai Waste Management, TNWML and Ramky Finance And Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Specialized in hazardous waste disposal, bio-medical management, and industrial services.
|
Locked | Locked | Locked | |
|
Offers hazardous waste treatment, disposal, and environmental consulting to industries.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Smilax Laboratories
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Smilax Laboratories
Investment portfolio details for Smilax Laboratories
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Smilax Laboratories
Detailed financials for Smilax Laboratories
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Smilax Laboratories Comparisons
Peer comparison for Smilax Laboratories
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Smilax Laboratories
Smilax Laboratories operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
Detailed competitors of Smilax Laboratories
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Smilax Laboratories
Complete news archive for Smilax Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Smilax Laboratories
Smilax Laboratories was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Smilax Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Smilax Laboratories is a funded company, having raised a total of $14.04M across 3 funding rounds to date.
As of Apr 10, 2024, the latest employee count at Smilax Laboratories is 521.
Annual revenue of Smilax Laboratories is $32.15M as on Mar 31, 2023.
Smilax Laboratories was established in 2005 in Hyderabad, India, within the pharmaceutical sector. Active pharmaceutical ingredients (APIs), chemical intermediates, and pellets are produced as core operations. The company is led by Suryadevara Krishna, serving as Founder and Managing Director, alongside Muralikrishna Suryadevara as Managing Director. Focus is placed on manufacturing processes tailored for pharmaceutical applications, with activities centered in India.
Smilax Laboratories's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Smilax Laboratories offers APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services.
Smilax Laboratories has 11 investors. Key investors include Mumbai Waste Management, TNWML, Ramky Finance And Investment, ADR Constructions, and Y R Nagaraja.
The valuation of Smilax Laboratories is $44.2M as of Nov 2017.